I-Mab (天境生物) Pre-IPO: Strong Management and Investor Backing with Differentiated Products
I-Mab, a rapidly growing Chinese biotech company, is looking to raise USD100 million via an IPO in the US. The company has a highly differentiated...
718 Views
𝛼SK or SearchENTITY
NovaBridge Biosciences (NBP US)
NovaBridge Biosciences (NBP US)
68
Analysis
Health Care • China
NovaBridge Biosciences is a biopharmaceutical company. The Company specializes in discovery, development, and commercialization of novel biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. NovaBridge Biosciences operates globally.
morex